What is SurgiVance?
SurgiVance specializes in advanced surgical pathology solutions designed to enhance cancer care through rapid, point-of-care diagnosis. Their integrated offerings encompass a Direct-to-Digital Pathology platform, a Point-of-Care Tabletop Imager, AI-powered image processing software, and disposable tissue specimen cassettes. The company's technology is targeted at oncology clinical care and research, providing critical tools for surgical margin screening and primary diagnosis. By prioritizing high diagnostic accuracy and a seamless user experience, SurgiVance is establishing the infrastructure for the future of digital pathology.
How much funding has SurgiVance raised?
SurgiVance has raised a total of $27K across 1 funding round:
Debt
$27K
Debt (2021): $27K with participation from PPP
What's next for SurgiVance?
With the recent influx of substantial expansion capital, SurgiVance is strategically positioned for significant scaling and further development of its innovative digital pathology solutions. This financing, occurring at a critical Series B/C stage, will likely fuel advancements in their AI-powered image processing and the broader adoption of their Direct-to-Digital Pathology platform. The company's focus on improving cancer care through rapid, accurate diagnosis at the point of care suggests future initiatives may involve expanding clinical partnerships, enhancing product capabilities, and potentially exploring new diagnostic applications within oncology and beyond. The investment underscores confidence in SurgiVance's trajectory to revolutionize pathology workflows.
See full SurgiVance company page
